Projects / Programmes
Proteolysis and its regulation
January 1, 2015
- December 31, 2021
Code |
Science |
Field |
Subfield |
1.05.00 |
Natural sciences and mathematics |
Biochemistry and molecular biology |
|
4.06.00 |
Biotechnical sciences |
Biotechnology |
|
Code |
Science |
Field |
B000 |
Biomedical sciences |
|
Code |
Science |
Field |
1.06 |
Natural Sciences |
Biological sciences |
proteases, cathepsins, caspases, legumain, inhibitors, activity-based probes, targeted-delivery systems, inflammation-associated diseases, cancer, arthritis, immunity, proteomics, chemogenomics
Researchers (55)
no. |
Code |
Name and surname |
Research area |
Role |
Period |
No. of publicationsNo. of publications |
1. |
36326 |
Teja Bajt |
Natural sciences and mathematics |
Junior researcher |
2015 |
0 |
2. |
39130 |
PhD Monika Biasizzo |
Natural sciences and mathematics |
Junior researcher |
2016 - 2021 |
23 |
3. |
32149 |
PhD Katja Bidovec |
Natural sciences and mathematics |
Junior researcher |
2015 - 2016 |
12 |
4. |
37546 |
PhD Janja Božič |
Medical sciences |
Researcher |
2015 - 2021 |
30 |
5. |
33315 |
PhD Miha Butinar |
Natural sciences and mathematics |
Researcher |
2015 - 2019 |
60 |
6. |
08327 |
PhD Kristina Djinovic Carugo |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
344 |
7. |
00449 |
PhD Iztok Dolenc |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
110 |
8. |
33160 |
PhD Sara Drmota Prebil |
Natural sciences and mathematics |
Junior researcher |
2015 |
12 |
9. |
54714 |
Ana Ercegovič Rot |
Natural sciences and mathematics |
Junior researcher |
2020 - 2021 |
3 |
10. |
18801 |
PhD Marko Fonović |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
173 |
11. |
36808 |
PhD Aljaž Gaber |
Natural sciences and mathematics |
Researcher |
2019 - 2021 |
69 |
12. |
39078 |
PhD Tjaša Goričan |
Natural sciences and mathematics |
Junior researcher |
2016 - 2021 |
17 |
13. |
38199 |
Marija Grozdanić |
Natural sciences and mathematics |
Junior researcher |
2015 - 2019 |
9 |
14. |
30872 |
PhD Maruša Hafner Česen |
Natural sciences and mathematics |
Researcher |
2015 - 2017 |
31 |
15. |
36335 |
PhD Katarina Hočevar |
Natural sciences and mathematics |
Junior researcher |
2015 - 2017 |
9 |
16. |
50500 |
Urban Javoršek |
Medical sciences |
Junior researcher |
2017 - 2021 |
9 |
17. |
50310 |
PhD Nežka Kavčič |
Natural sciences and mathematics |
Researcher |
2017 - 2021 |
37 |
18. |
54695 |
Matej Kolarič |
Natural sciences and mathematics |
Junior researcher |
2020 - 2021 |
7 |
19. |
10502 |
PhD Nataša Kopitar Jerala |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
235 |
20. |
38198 |
PhD Andreja Kozak |
Medical sciences |
Researcher |
2015 - 2021 |
21 |
21. |
37474 |
Aleksander Krajnc |
Natural sciences and mathematics |
Junior researcher |
2015 - 2018 |
11 |
22. |
37408 |
PhD Anja Krajnc |
Natural sciences and mathematics |
Junior researcher |
2015 - 2016 |
7 |
23. |
35467 |
PhD Lovro Kramer |
Natural sciences and mathematics |
Researcher |
2015 - 2017 |
40 |
24. |
03422 |
PhD Brigita Lenarčič |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
336 |
25. |
53032 |
Petra Matjan Štefin |
Natural sciences and mathematics |
Junior researcher |
2019 - 2021 |
7 |
26. |
37797 |
PhD Georgy Mikhaylov |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
53 |
27. |
26028 |
PhD Marko Novinec |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
205 |
28. |
35318 |
Maja Orehek |
|
Technical associate |
2020 - 2021 |
0 |
29. |
37465 |
PhD Sabina Ott Rutar |
Natural sciences and mathematics |
Junior researcher |
2015 - 2016 |
11 |
30. |
23575 |
PhD Miha Pavšič |
Natural sciences and mathematics |
Researcher |
2021 |
182 |
31. |
29470 |
PhD Katarina Pegan |
Natural sciences and mathematics |
Researcher |
2015 - 2016 |
44 |
32. |
29966 |
Dejan Pelko |
|
Technical associate |
2015 - 2021 |
0 |
33. |
09091 |
PhD Vida Puizdar |
Natural sciences and mathematics |
Researcher |
2015 - 2020 |
55 |
34. |
35337 |
PhD Vid Puž |
Natural sciences and mathematics |
Junior researcher |
2015 - 2016 |
14 |
35. |
34212 |
PhD Jelena Rajković |
Natural sciences and mathematics |
Researcher |
2016 - 2017 |
21 |
36. |
21560 |
PhD Urška Repnik |
Medical sciences |
Researcher |
2015 - 2016 |
149 |
37. |
17096 |
Andreja Sekirnik |
Natural sciences and mathematics |
Technical associate |
2015 - 2017 |
26 |
38. |
52063 |
Tilen Sever |
Natural sciences and mathematics |
Junior researcher |
2018 - 2021 |
12 |
39. |
55799 |
Tea Sinožić |
Natural sciences and mathematics |
Junior researcher |
2021 |
4 |
40. |
29542 |
PhD Barbara Sobotič |
Natural sciences and mathematics |
Researcher |
2015 - 2016 |
60 |
41. |
14829 |
PhD Veronika Stoka |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
235 |
42. |
06688 |
PhD Andrej Šali |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
57 |
43. |
15969 |
Ivica Štefe |
Natural sciences and mathematics |
Technical associate |
2015 - 2021 |
34 |
44. |
05234 |
Mojca Trstenjak Prebanda |
Natural sciences and mathematics |
Technical associate |
2015 - 2021 |
60 |
45. |
07561 |
PhD Boris Turk |
Natural sciences and mathematics |
Head |
2015 - 2021 |
1,019 |
46. |
01085 |
PhD Vito Turk |
Natural sciences and mathematics |
Retired researcher |
2015 - 2021 |
1,487 |
47. |
21619 |
PhD Olga Vasiljeva |
Medical sciences |
Researcher |
2015 - 2021 |
181 |
48. |
50513 |
Eva Vidak |
Natural sciences and mathematics |
Junior researcher |
2017 - 2021 |
15 |
49. |
33762 |
PhD Robert Vidmar |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
109 |
50. |
32171 |
PhD Matej Vizovišek |
Natural sciences and mathematics |
Researcher |
2015 - 2018 |
118 |
51. |
52068 |
Miki Zarić |
Natural sciences and mathematics |
Junior researcher |
2018 - 2021 |
13 |
52. |
18286 |
PhD Tina Zavašnik Bergant |
Natural sciences and mathematics |
Researcher |
2015 - 2018 |
138 |
53. |
34458 |
PhD Janja Završnik |
Natural sciences and mathematics |
Researcher |
2015 - 2018 |
51 |
54. |
51998 |
Tomaž Žagar |
Natural sciences and mathematics |
Junior researcher |
2018 - 2021 |
7 |
55. |
03368 |
PhD Eva Žerovnik |
Natural sciences and mathematics |
Researcher |
2015 - 2021 |
386 |
Organisations (2)
Abstract
Proteolytic processing is one of the most important irreversible post translational protein modifications. Through processing and/or degradation proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Their action is strictly controlled and imbalances in their activities have been found to be critical in a number of pathologies, such as inflammation, cancer and neurodegenerative diseases, thereby suggesting proteases as suitable and valuable drug targets. Especially in inflammation, which plays a major role in disease onset and progression in a vast number of diseases, including various cancers and arthritis, proteases have very important roles. These disease-associated proteases include cysteine cathepsins, metalloproteases, some caspases and aspartic cathepsins that can be found at the sites of inflammation. As in most of these diseases there is an urgent clinical need for improved diagnosis, therapies and patient welfare, the major focus of our program will be on cysteine cathepsins, for which unambiguous evidence for their major roles in diseases, such as cancer, atherosclerosis and rheumatoid arthritis, has been provided using genetic ablation and pharmacological inhibition in animal models. In addition to cathepsins, caspases, legumain, various metalloproteases, autophagins and aspartic cathepsins will be investigated. However, understanding the precise role of an individual protease in a disease remains a major challenge for successful therapeutic applications. The major goal of our program is therefore to further understand the signaling pathways by which selected proteases regulate physiological processes in health and disease and to understand interactions governing this signaling at the molecular level, including regulation of their activities with major focus on inflammation-associated diseases. Part of the activities will focus on the development of tools and approaches, which could be exploited for disease diagnosis and therapy, including monitoring protease activities, regulating protease activities in disease states or identifying protease signaling pathways. A major potential in this aspect have the novel activity-based probes for diagnostic imaging and especially novel targeted drug delivery systems with theranostic potential. Moreover, the identified protease substrates in the disease context have a significant biomarker potential, which will be explored in human and animal clinical samples. We therefore believe that this research will enhance our understanding of protease signaling pathways and their regulation in health and disease progression at the molecular level, our ability to diagnose disease and monitor its progression, and improve the existing therapeutic opportunities, which would take personalized medicine to the next level.
Significance for science
Proteolytic enzymes play a key role in intra- and extracellular protein processing and degradation, which are among the most important physiological processes. Under normal conditions proteolysis is a highly regulated process, where protease activities are largely controlled by activation of inactive zymogens and through inhibition by endogenous inhibitors. However, when regulation fails, proteases can be extremely harmfull for the organism, leading to numerous diseases (Turk 2006; Drag and Salvesen, 2010; Turk et al., 2012). In the past, our research group has contributed significantly to the development of the field with the discoveries of several cathepsins and their endogenous inhibitors cystatin C, stefins A and B, kininogens and thyropins, lysosomal pathway to apoptosis, , understanding the role of autophagy in T. cruzi, as well as pioneering efforts in the fields of development of novel nanoparticle-based targeted drug delivery systems, allosteric protease inhibitors and novel activity-based probes for proteases which classify our research at the cutting edge in the field. This is reflected also in high citation of our works in this competitive field. The proposed research program offers new possibilities for further understanding of protease regulation, including its role in inflammation-associated diseases (cancer, arthritis, inflammatory bowel diseases, etc.), as well as possibilities for rational drug design, biomarker discovery and other novel diagostic and therapeutic opportunities, including development of novel theranostic systems on a way towards personalized medicine. Therefore, we have good arguments to expect that the proposed research will be accomplished succesfully also in the next six year period. A major interest of the pharmaceutical companies for proteases including the cathepsins (the first cathepsin targeting drug odanacatib for osteoporosis treatment is expected to be filed to FDA soon) is supporting the idea that this problematics is extremely important. Moreover, the research topics are also among the topics of Horizon2020 research programmes. It can be concluded that the proposed research topics belong among the most attractive areas of research in the fields of biomedicine, agriculture and farmacy, to list just some of them. A further confirmation for the high level of scientific achievements of the group is evident from numerous publications in the most important international journals, including several publications in the journals with IF ) 9.0 in the last programme (2009-2014) and consequently the high citation of the works of the programme leader (over 6600 citations total, H-index 42), as well as of the other researchers. Moreover, this is evident also from the numerous awards received by research group members as well as from the list of international collaborations with a number of top class researchers worldwide.
Significance for the country
Although the proposed research is basic research, it also has its applied component and can be classified as strategic basic research. Members of the group have extensively collaborated with Slovene (Lek, Krka, Medis, Acies Bio, …) and foreign industry (Sanofi), which resulted in a substantial amount of contract-based research and FP7 projects, as well as extensive collaborations within the Center of Excellence CIPKEBIP and the Competence Center Brin, which have been both financed by European Structural Funds. Moreover, as a result several international patents have been filed and/or granted. The work also offers great opportunity for students to be trained in the most advanced methods and areas, such as proteomics (the only proteomics facility in Slovenia), chemogenomics, targeted drug delivery and in vivo imaging (the only in vivo imaging system in Slovenia). All these fields have namely high international priority as they are of extreme importance in modern drug discovery and early diagnostics, and combining them should help translate the findings into clinics and bring the personal medicine to a new level. It is therefore not suprising that research within this programme since its beginning lead to over 250 finished BSc theses, over 40 MSc theses and over 40 PhD theses, including 12 in the last programme call since 2009. After finishing their studies, numerous researchers left the group and went to other institutes and universities. At the University of Ljubljana (UL) researchers from this programme form the core of the biochemistry program and chair of biochemistry at FKKT UL. A number of the researchers from the programme went to pharmaceutical industry (over 10 in last 7-8 years).
Investigations like this combining biochemistry, chemogenomics, proteomics and molecular and cell biology are critically important for the development of modern biotechnology and biomedical research. Excellent and up-to-date science and its transfer to modern technology are of major importance for the sustainable socio-economic development and competitiveness of Slovenia and its classification among the developed members of EC. In addition, members of the project team have received wide-spread international recognition, which is very important for the world-wide promotion of Slovenia and as such also for preservation of national identity of Slovenia. The group organized a number of international meetings with participation of numerous excellent foreign researchers from academia and industry, including several Nobel laureates. A number of international collaborations have been established, which all contributes to the international reputation of Slovenia. Group members also served important functions in governing bodies of various International organizations. Dr. Boris Turk is currently Secretary General of European Cell Death Organization (ECDO), he was councilor of the International Proteolysis Society (IPS, 2001-2005; 2009-2013) andt its Secretary (2009-2011) and President (2011-2013), he is an EMBO member and member of Academia Europea (London) and was awarded Zois award for outstanding achievements in the field of Protease signaling in 2011. Dr. Vito Turk was performing leading functions in the Federation of European Biochemical Societies (FEBS) and in IUBMB, he is a member of Slovene Academy of Sciences and Arts, EMBO, European Academy (London), etc. In addition, other group members also received various awards and amendments. Furthermore, several group members serve as Editors or Editorial board members of various international journals, which additionally contribute to international recognition of Slovenia. With our achievements we contribute also to the cultural rise of Slovenia as both science and arts are indispensable for that.
Most important scientific results
Annual report
2015,
interim report
Most important socioeconomically and culturally relevant results
Annual report
2015,
interim report